Maia Kayal, MD, MS, defines interchangeability and reviews the requirements from the FDA, "switching studies," and meaningful difference verses class effect.
A panel of experts review the emerging interchangeable biosimilars and best practices on how to educate providers and patients on interchangeable biosimilars.